VANCOUVER, British Columbia / Aug 12, 2025 / Business Wire / AbCellera (Nasdaq: ABCL) today announced that the Company will participate in the following investor conferences:
Visit AbCellera's Investor Relations website for additional information.
About AbCellera Biologics Inc.
AbCellera (Nasdaq: ABCL) is a clinical-stage biotechnology company focused on discovering and developing antibody-based medicines in the areas of endocrinology, women's health, immunology, and oncology. For more information, please visit www.abcellera.com.
| Last Trade: | US$3.57 |
| Daily Change: | 0.06 1.71 |
| Daily Volume: | 6,704,974 |
| Market Cap: | US$1.070B |
November 10, 2025 November 06, 2025 August 07, 2025 May 30, 2025 | |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
